Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IPSC Century Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: IPSC
Price (delayed)
$0.6182
Market cap
$53.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.29
Enterprise value
$46.42M
Highlights
The EPS has surged by 87% year-on-year and by 82% since the previous quarter
Century Therapeutics's net income has soared by 84% YoY and by 83% from the previous quarter
The debt has grown by 8% year-on-year but it has declined by 2.4% since the previous quarter
The quick ratio has declined by 4.1% year-on-year
Key stats
What are the main financial stats of IPSC
Market
Valuations
Earnings
Shares outstanding
86.16M
Market cap
$53.26M
Enterprise value
$46.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.22
Price to sales (P/S)
0.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.4
Revenue
$114.9M
Gross profit
$114.9M
Operating income
-$32.65M
Net income
-$21.95M
EBIT
-$20.16M
EBITDA
-$8.4M
Free cash flow
-$114.6M
Per share
Balance sheet
Liquidity
EPS
-$0.29
EPS diluted
-$0.29
Free cash flow per share
-$1.33
Book value per share
$2.79
Revenue per share
$1.34
TBVPS
$3.27
Total assets
$315.61M
Total liabilities
$75.17M
Debt
$47.79M
Equity
$240.44M
Working capital
$155.13M
Debt to equity
0.2
Current ratio
11.7
Quick ratio
11.58
Net debt/EBITDA
0.82
Margins
Efficiency
Dividend
EBITDA margin
-7.3%
Gross margin
100%
Net margin
-19.1%
Operating margin
-28.4%
Return on assets
-6%
Return on equity
-10.7%
Return on invested capital
-7.1%
Return on capital employed
-6.7%
Return on sales
-17.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IPSC stock price
How has the Century Therapeutics stock price performed over time
Intraday
-1.2%
1 week
11.37%
1 month
-2.61%
1 year
-73.81%
YTD
-38.79%
QTD
10.65%
Financial performance
How have Century Therapeutics's revenue and profit performed over time
Revenue
$114.9M
Gross profit
$114.9M
Operating income
-$32.65M
Net income
-$21.95M
Gross margin
100%
Net margin
-19.1%
Century Therapeutics's operating margin has surged by 100% YoY and by 99% QoQ
The net margin has surged by 100% year-on-year and by 99% since the previous quarter
Century Therapeutics's net income has soared by 84% YoY and by 83% from the previous quarter
The company's operating income has surged by 78% YoY and by 76% QoQ
Price vs fundamentals
How does IPSC's price correlate with its fundamentals
Growth
What is Century Therapeutics's growth rate over time
Valuation
What is Century Therapeutics stock price valuation
P/E
N/A
P/B
0.22
P/S
0.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.4
The EPS has surged by 87% year-on-year and by 82% since the previous quarter
IPSC's price to book (P/B) is 84% lower than its 5-year quarterly average of 1.4 and 63% lower than its last 4 quarters average of 0.6
The equity is up by 49% since the previous quarter and by 35% year-on-year
The price to sales (P/S) is 99% lower than the last 4 quarters average of 42.2
Efficiency
How efficient is Century Therapeutics business performance
The return on sales has surged by 100% year-on-year and by 99% since the previous quarter
Century Therapeutics's ROE has soared by 84% from the previous quarter and by 83% YoY
Century Therapeutics's return on assets has surged by 83% YoY and by 82% QoQ
The ROIC has soared by 83% from the previous quarter and by 81% YoY
Dividends
What is IPSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IPSC.
Financial health
How did Century Therapeutics financials performed over time
Century Therapeutics's total liabilities has shrunk by 61% QoQ and by 56% YoY
Century Therapeutics's total assets has decreased by 11% QoQ and by 9% YoY
The debt is 80% smaller than the equity
The equity is up by 49% since the previous quarter and by 35% year-on-year
IPSC's debt to equity is down by 33% since the previous quarter and by 20% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.